研究者業績

平原 潔

ヒラハラ キヨシ  (Kiyoshi Hirahara)

基本情報

所属
千葉大学 大学院医学研究院先端研究部門高次機能治療学研究講座免疫発生学 教授
学位
博士(医学)(新潟大学)

研究者番号
00707193
J-GLOBAL ID
201801001136657946
researchmap会員ID
B000302077

2001年新潟大学医学部卒。2008年同大学院医歯学総合研究科修了。医学博士。
2009年米国国立衛生研究所 Visiting Fellow、2013年千葉大学大学院医学研究院特任准教授を経て、2016年より千葉大学大学院医学研究院准教授、2022年より同教授(現職)。
内科医(特に呼吸器内科医)として、5年以上臨床医療に携わった後、基礎医学研究の世界へ飛び込みました。ベッドサイドへのフィ-ドバックを目標とした基礎研究確立を希い、日々研究活動に勤しんでいます。

専門分野:免疫学、呼吸器内科学
現在の主要なテーマ:
*肺線維化における獲得免疫系の役割
*組織常在性記憶CD4 T細胞の分化・維持機構
*アレルギー疾患の病態形成機構
*肺における免疫応答一般


論文

 92
  • Tatsuya Kaneko, Chiaki Iwamura, Masahiro Kiuchi, Akane Kurosugi, Miki Onoue, Tomoaki Matsumura, Tetsuhiro Chiba, Toshinori Nakayama, Naoya Kato, Kiyoshi Hirahara
    Journal of Allergy and Clinical Immunology: Global 100287-100287 2024年6月  査読有り
  • Ami Aoki, Chiaki Iwamura, Masahiro Kiuchi, Kaori Tsuji, Atsushi Sasaki, Takahisa Hishiya, Rui Hirasawa, Kota Kokubo, Sachiko Kuriyama, Atsushi Onodera, Tadanaga Shimada, Tetsutaro Nagaoka, Satoru Ishikawa, Akira Kojima, Haruki Mito, Ryota Hase, Yasunori Kasahara, Naohide Kuriyama, Sukeyuki Nakamura, Takashi Urushibara, Satoru Kaneda, Seiichiro Sakao, Osamu Nishida, Kazuhisa Takahashi, Motoko Y. Kimura, Shinichiro Motohashi, Hidetoshi Igari, Yuzuru Ikehara, Hiroshi Nakajima, Takuji Suzuki, Hideki Hanaoka, Taka-aki Nakada, Toshiaki Kikuchi, Toshinori Nakayama, Koutaro Yokote, Kiyoshi Hirahara
    Journal of Clinical Immunology 44(4) 2024年4月22日  査読有り
    Abstract Purpose Auto-antibodies (auto-abs) to type I interferons (IFNs) have been identified in patients with life-threatening coronavirus disease 2019 (COVID-19), suggesting that the presence of auto-abs may be a risk factor for disease severity. We therefore investigated the mechanism underlying COVID-19 exacerbation induced by auto-abs to type I IFNs. Methods We evaluated plasma from 123 patients with COVID-19 to measure auto-abs to type I IFNs. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells from the patients with auto-abs and conducted epitope mapping of the auto-abs. Results Three of 19 severe and 4 of 42 critical COVID-19 patients had neutralizing auto-abs to type I IFNs. Patients with auto-abs to type I IFNs showed no characteristic clinical features. scRNA-seq from 38 patients with COVID-19 revealed that IFN signaling in conventional dendritic cells and canonical monocytes was attenuated, and SARS-CoV-2-specific BCR repertoires were decreased in patients with auto-abs. Furthermore, auto-abs to IFN-α2 from COVID-19 patients with auto-abs recognized characteristic epitopes of IFN-α2, which binds to the receptor. Conclusion Auto-abs to type I IFN found in COVID-19 patients inhibited IFN signaling in dendritic cells and monocytes by blocking the binding of type I IFN to its receptor. The failure to properly induce production of an antibody to SARS-CoV-2 may be a causative factor of COVID-19 severity.
  • Ryo Hatano, Eunyoung Lee, Hiromi Sato, Masahiro Kiuchi, Kiyoshi Hirahara, Yoshimi Nakagawa, Hitoshi Shimano, Toshinori Nakayama, Tomoaki Tanaka, Takashi Miki
    Molecular Metabolism 101934-101934 2024年4月  査読有り
  • Shigeru Tanaka, Takuya Yamamoto, Arifumi Iwata, Masahiro Kiuchi, Kota Kokubo, Tomohisa Iinuma, Takahiro Sugiyama, Toyoyuki Hanazawa, Kiyoshi Hirahara, Kei Ikeda, Hiroshi Nakajima
    Arthritis research & therapy 26(1) 55-55 2024年2月20日  査読有り
    OBJECTIVES: IgG4-related disease (IgG4-RD) is a systemic autoimmune disease with an unknown etiology, affecting single/multiple organ(s). Pathological findings include the infiltration of IgG4-producing plasma cells, obliterative phlebitis, and storiform fibrosis. Although immunological studies have shed light on the dysregulation of lymphocytes in IgG4-RD pathogenesis, the role of non-immune cells remains unclear. This study aimed to investigate the demographics and characteristics of non-immune cells in IgG4-RD and explore potential biomarkers derived from non-immune cells in the sera. METHODS: We conducted single-cell RNA sequence (scRNA-seq) on non-immune cells isolated from submandibular glands of IgG4-RD patients. We focused on fibroblasts expressing collagen type XV and confirmed the presence of those fibroblasts using immunohistochemistry. Additionally, we measured the levels of collagen type XV in the sera of IgG4-RD patients. RESULTS: The scRNA-seq analysis revealed several distinct clusters consisting of fibroblasts, endothelial cells, ductal cells, and muscle cells. Differential gene expression analysis showed upregulation of COL15A1 in IgG4-RD fibroblasts compared to control subjects. Notably, COL15A1-positive fibroblasts exhibited a distinct transcriptome compared to COL15A1-negative counterparts. Immunohistochemical analysis confirmed a significant presence of collagen type XV-positive fibroblasts in IgG4-RD patients. Furthermore, immune-suppressive therapy in active IgG4-RD patients resulted in decreased serum levels of collagen type XV. CONCLUSIONS: Our findings suggest that collagen type XV-producing fibroblasts may represent a disease-characterizing non-immune cell population in IgG4-RD and hold potential as a disease-monitoring marker.
  • Jin Kumagai, Masahiro Kiuchi, Kota Kokubo, Hiroyuki Yagyu, Masahiro Nemoto, Kaori Tsuji, Ken Nagahata, Atsushi Sasaki, Takahisa Hishiya, Miki Onoue, Rie Shinmi, Yuri Sonobe, Tomohisa Iinuma, Syuji Yonekura, Jun Shinga, Toyoyuki Hanazawa, Haruhiko Koseki, Toshinori Nakayama, Koutaro Yokote, Kiyoshi Hirahara
    Proceedings of the National Academy of Sciences of the United States of America 120(49) e2302903120 2023年12月5日  査読有り
    Uncontrolled type 2 immunity by type 2 helper T (Th2) cells causes intractable allergic diseases; however, whether the interaction of CD4+ T cells shapes the pathophysiology of allergic diseases remains unclear. We identified a subset of Th2 cells that produced the serine proteases granzyme A and B early in differentiation. Granzymes cleave protease-activated receptor (Par)-1 and induce phosphorylation of p38 mitogen-activated protein kinase (MAPK), resulting in the enhanced production of IL-5 and IL-13 in both mouse and human Th2 cells. Ubiquitin-specific protease 7 (USP7) regulates IL-4-induced phosphorylation of STAT3, resulting in granzyme production during Th2 cell differentiation. Genetic deletion of Usp7 or Gzma and pharmacological blockade of granzyme B ameliorated allergic airway inflammation. Furthermore, PAR-1+ and granzyme+ Th2 cells were colocalized in nasal polyps from patients with eosinophilic chronic rhinosinusitis. Thus, the USP7-STAT3-granzymes-Par-1 pathway is a potential therapeutic target for intractable allergic diseases.
  • Atsushi Onodera, Kota Kokubo, Mikiko Okano, Miki Onoue, Masahiro Kiuchi, Chiaki Iwamura, Tomohisa Iinuma, Motoko Y. Kimura, Nobuyuki Ebihara, Toyoyuki Hanazawa, Toshinori Nakayama, Kiyoshi Hirahara
    Pharmacology & Therapeutics 247 108445-108445 2023年7月  査読有り
  • Kensuke Suga, Masahiro Kiuchi, Takahiro Kageyama, Kota Kokubo, Shigeru Tanaka, Arifumi Iwata, Kotaro Suzuki, Kiyoshi Hirahara, Hiroshi Nakajima
    Allergology international : official journal of the Japanese Society of Allergology 2023年6月20日  査読有り
  • Ryo Koyama-Nasu, Motoko Y Kimura, Masahiro Kiuchi, Ami Aoki, Yangsong Wang, Yukiyoshi Mita, Ichita Hasegawa, Yukihiro Endo, Atsushi Onodera, Kiyoshi Hirahara, Shinichiro Motohashi, Toshinori Nakayama
    Cancer immunology research 2023年5月22日  査読有り
    Tumor-specific CD8+ T cells play a pivotal role in anti-tumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stem-like CD8+ T cells give rise to their cytotoxic progeny - Tim-3+ terminally differentiated CD8+ T cells. However, where and how this differentiation process occurs has not been elucidated. We herein show that terminally differentiated CD8+ T cells can be generated within tumor-draining lymph nodes (TDLNs) and that CD69 expression on tumor-specific CD8+ T cells controls its differentiation process through regulating the expression of the transcription factor TOX. In TDLNs, CD69 deficiency diminished TOX expression in tumor-specific CD8+ T cells, and consequently promoted generation of functional terminally differentiated CD8+ T cells. Anti-CD69 administration promoted the generation of terminally differentiated CD8+ T cells, and the combined use of anti-CD69 and anti-PD-1 showed an efficient anti-tumor effect. Thus, CD69 is an attractive target for cancer immunotherapy that synergizes with immune checkpoint blockade.
  • Tomohisa Iinuma, Syuji Yonekura, Kiyoshi Hirahara, Junya Kurita, Riyo Yoneda, Tomoyuki Arai, Yuri Sonobe, Rie Shinmi, Yoshitaka Okamoto, Toyoyuki Hanazawa
    Allergology International 2023年5月  査読有り
  • Yuki Sato, Karina Silina, Maries van den Broek, Kiyoshi Hirahara, Motoko Yanagita
    Nature reviews. Nephrology 19(8) 525-537 2023年4月12日  査読有り
    Tertiary lymphoid structures (TLSs) are ectopic lymphoid tissues that drive antigen-specific immune responses at sites of chronic inflammation. Unlike secondary lymphoid organs such as lymph nodes, TLSs lack capsules and have their own unique characteristics and functions. The presumed influence of TLSs on the disease course has led to widespread interest in obtaining a better understanding of their biology and function. Studies using single-cell analyses have suggested heterogeneity in TLS composition and phenotype, and consequently, functional correlates with disease progression are sometimes conflicting. The presence of TLSs correlates with a favourable disease course in cancer and infection. Conversely, in autoimmune diseases and chronic age-related inflammatory diseases including chronic kidney disease, the presence of TLSs is associated with a more severe disease course. However, the detailed mechanisms that underlie these clinical associations are not fully understood. To what extent the mechanisms of TLS development and maturation are shared across organs and diseases is also still obscure. Improved understanding of TLS development and function at the cellular and molecular levels may enable the exploitation of these structures to improve therapies for chronic diseases, including chronic kidney disease.
  • Kota Kokubo, Kiyoshi Hirahara, Masahiro Kiuchi, Kaori Tsuji, Yuki Shimada, Yuri Sonobe, Rie Shinmi, Takahisa Hishiya, Chiaki Iwamura, Atsushi Onodera, Toshinori Nakayama
    Proceedings of the National Academy of Sciences of the United States of America 120(2) e2218345120 2023年1月10日  査読有り
    CD4+ memory T cells are central to long-lasting protective immunity and are involved in shaping the pathophysiology of chronic inflammation. While metabolic reprogramming is critical for the generation of memory T cells, the mechanisms controlling the redox metabolism in memory T cell formation remain unclear. We found that reactive oxygen species (ROS) metabolism changed dramatically in T helper-2 (Th2) cells during the contraction phase in the process of memory T cell formation. Thioredoxin-interacting protein (Txnip), a regulator of oxidoreductase, regulated apoptosis by scavenging ROS via the nuclear factor erythroid 2-related factor 2 (Nrf2)-biliverdin reductase B (Blvrb) pathway. Txnip regulated the pathology of chronic airway inflammation in the lung by controlling the generation of allergen-specific pathogenic memory Th2 cells in vivo. Thus, the Txnip-Nrf2-Blvrb axis directs ROS metabolic reprogramming in Th2 cells and is a potential therapeutic target for intractable chronic inflammatory diseases.
  • Kaori Tsuji, Ami Aoki, Atsushi Onodera, Masahiro Kiuchi, Kota Kokubo, Yuki Morimoto, Tomohisa Iinuma, Toyoyuki Hanazawa, Toshinori Nakayama, Kiyoshi Hirahara
    Allergology International in press(2) 335-338 2022年12月  査読有り
  • Mikiko Okano, Kiyoshi Hirahara, Masahiro Kiuchi, Miki Onoue, Chiaki Iwamura, Kota Kokubo, Takahisa Hishiya, Yuki Morimoto, Yuzuru Ikehara, Akira Murakami, Nobuyuki Ebihara, Toshinori Nakayama
    Immunity 55(12) 2352-2368.e7 2022年10月  査読有り
  • Tomohisa Iinuma, Masahiro Kiuchi, Kiyoshi Hirahara, Junya Kurita, Kota Kokubo, Hiroyuki Yagyu, Riyo Yoneda, Tomoyuki Arai, Yuri Sonobe, Masaki Fukuyo, Atsushi Kaneda, Syuji Yonekura, Toshinori Nakayama, Yoshitaka Okamoto, Toyoyuki Hanazawa
    Journal of Allergy and Clinical Immunology 150(4) 850-860.e5 2022年10月  査読有り
  • Masanori Fujimoto, Masataka Yokoyama, Masahiro Kiuchi, Hiroyuki Hosokawa, Akitoshi Nakayama, Naoko Hashimoto, Ikki Sakuma, Hidekazu Nagano, Kazuyuki Yamagata, Fujimi Kudo, Ichiro Manabe, Eunyoung Lee, Ryo Hatano, Atsushi Onodera, Kiyoshi Hirahara, Koutaro Yokote, Takashi Miki, Toshinori Nakayama, Tomoaki Tanaka
    Nature Communications 13(1) 2022年9月15日  査読有り
    Abstract The liver stores glycogen and releases glucose into the blood upon increased energy demand. Group 2 innate lymphoid cells (ILC2) in adipose and pancreatic tissues are known for their involvement in glucose homeostasis, but the metabolic contribution of liver ILC2s has not been studied in detail. Here we show that liver ILC2s are directly involved in the regulation of blood glucose levels. Mechanistically, interleukin (IL)-33 treatment induces IL-13 production in liver ILC2s, while directly suppressing gluconeogenesis in a specific Hnf4a/G6pc-high primary hepatocyte cluster via Stat3. These hepatocytes significantly interact with liver ILC2s via IL-13/IL-13 receptor signaling. The results of transcriptional complex analysis and GATA3-ChIP-seq, ATAC-seq, and scRNA-seq trajectory analyses establish a positive regulatory role for the transcription factor GATA3 in IL-13 production by liver ILC2s, while AP-1 family members are shown to suppress IL-13 release. Thus, we identify a regulatory role and molecular mechanism by which liver ILC2s contribute to glucose homeostasis.
  • Chiaki Iwamura, Kiyoshi Hirahara, Masahiro Kiuchi, Sanae Ikehara, Kazuhiko Azuma, Tadanaga Shimada, Sachiko Kuriyama, Syota Ohki, Emiri Yamamoto, Yosuke Inaba, Yuki Shiko, Ami Aoki, Kota Kokubo, Rui Hirasawa, Takahisa Hishiya, Kaori Tsuji, Tetsutaro Nagaoka, Satoru Ishikawa, Akira Kojima, Haruki Mito, Ryota Hase, Yasunori Kasahara, Naohide Kuriyama, Tetsuya Tsukamoto, Sukeyuki Nakamura, Takashi Urushibara, Satoru Kaneda, Seiichiro Sakao, Minoru Tobiume, Yoshio Suzuki, Mitsuhiro Tsujiwaki, Terufumi Kubo, Tadashi Hasegawa, Hiroshi Nakase, Osamu Nishida, Kazuhisa Takahashi, Komei Baba, Yoko Iizumi, Toshiya Okazaki, Motoko Y. Kimura, Ichiro Yoshino, Hidetoshi Igari, Hiroshi Nakajima, Takuji Suzuki, Hideki Hanaoka, Taka-aki Nakada, Yuzuru Ikehara, Koutaro Yokote, Toshinori Nakayama
    Proceedings of the National Academy of Sciences 119(33) 2022年8月16日  査読有り
    The mortality of coronavirus disease 2019 (COVID-19) is strongly correlated with pulmonary vascular pathology accompanied by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection–triggered immune dysregulation and aberrant activation of platelets. We combined histological analyses using field emission scanning electron microscopy with energy-dispersive X-ray spectroscopy analyses of the lungs from autopsy samples and single-cell RNA sequencing of peripheral blood mononuclear cells to investigate the pathogenesis of vasculitis and immunothrombosis in COVID-19. We found that SARS-CoV-2 accumulated in the pulmonary vessels, causing exudative vasculitis accompanied by the emergence of thrombospondin-1–expressing noncanonical monocytes and the formation of myosin light chain 9 (Myl9)–containing microthrombi in the lung of COVID-19 patients with fatal disease. The amount of plasma Myl9 in COVID-19 was correlated with the clinical severity, and measuring plasma Myl9 together with other markers allowed us to predict the severity of the disease more accurately. This study provides detailed insight into the pathogenesis of vasculitis and immunothrombosis, which may lead to optimal medical treatment for COVID-19.
  • Kota Kokubo, Atsushi Onodera, Masahiro Kiuchi, Kaori Tsuji, Kiyoshi Hirahara, Toshinori Nakayama
    Frontiers in Immunology 13 2022年8月9日  査読有り
    Type 2 helper T (Th2) cells, a subset of CD4+ T cells, play an important role in the host defense against pathogens and allergens by producing Th2 cytokines, such as interleukin-4 (IL-4), IL-5, and IL-13, to trigger inflammatory responses. Emerging evidence reveals that Th2 cells also contribute to the repair of injured tissues after inflammatory reactions. However, when the tissue repair process becomes chronic, excessive, or uncontrolled, pathological fibrosis is induced, leading to organ failure and death. Thus, proper control of Th2 cells is needed for complete tissue repair without the induction of fibrosis. Recently, the existence of pathogenic Th2 (Tpath2) cells has been revealed. Tpath2 cells produce large amounts of Th2 cytokines and induce type 2 inflammation when activated by antigen exposure or tissue injury. In recent studies, Tpath2 cells are suggested to play a central role in the induction of type 2 inflammation whereas the role of Tpath2 cells in tissue repair and fibrosis has been less reported in comparison to conventional Th2 cells. In this review, we discuss the roles of conventional Th2 cells and pathogenic Th2 cells in the sequence of tissue inflammation, repair, and fibrosis.
  • Ken Wakai, Kazuhiko Azuma, Chiaki Iwamura, Maihulan Maimaiti, Kosuke Mikami, Kei Yoneda, Shinichi Sakamoto, Sanae Ikehara, Takashi Yamaguchi, Kiyoshi Hirahara, Tomohiko Ichikawa, Toshinori Nakayama, Yuzuru Ikehara
    Scientific Reports 12(1) 2022年5月31日  査読有り
    Abstract In bronchial asthma patients, mucous cell metaplasia (MCM) and fibrosis occur in the bronchial epithelium and interstitium, respectively. The mucus and collagen fibers are identified by Periodic acid-Schiff stain (PAS) or Sirius red stain on optical microscopy. On a scanning electron microscope (SEM) observation, formalin-fixed-paraffin-embedded specimens have high insulation, thereby attenuating the scattered electron signals leading to insufficient contrast. Moreover, there were no staining methods for SEM observation, which characterizes the changes in epithelium and interstitium by enhancing the scattered electrons. In this study, we established a method of coating osmium thin film on pathological tissue specimens using plasma chemical vapor deposition technology. This method ensured the intensity of scattered electron signals and enabled SEM observation. Furthermore, we found that morphological changes in MCM and interstitial fibrosis could be characterized by Grocott stain, which we optimized to evaluate pathological remodeling in bronchial asthma. Using these techniques, we compared asthma-induced mice with Amphiregulin (Areg) knockout mice, and found that Areg induce MCM, but the production of Grocott-stain-positive substrate in the interstitium is Areg-independent. The method developed in this study provides an understanding of the pathological spatial information linked to the ultrastructural changes in cells and interstitium due to disease-related signaling abnormalities.
  • Kenta Shinoda, Andrea Choe, Kiyoshi Hirahara, Masahiro Kiuchi, Kota Kokubo, Tomomi Ichikawa, Jason S. Hoki, Akane S. Suzuki, Neelanjan Bose, Judith A. Appleton, Raffi V. Aroian, Frank C. Schroeder, Paul W. Sternberg, Toshinori Nakayama
    Proceedings of the National Academy of Sciences 119(9) 2022年3月  査読有り
    Significance Animal proof-of-concept studies have shown that roundworms have a protective effect against immune-dysregulated disorders, but it has been difficult to study in human trials without individual nematode-derived molecules to develop and test. We discovered that ascarosides, molecules that are secreted by diverse nematodes, suppress asthma in a rodent model via modulation of expression of Il33 , a key epithelial cytokine for induction of type 2 immunity, in addition to decreasing memory-type pathogenic Th2 cells and ILC2s and increasing the Il10- expressing subpopulation of interstitial macrophages in the lung. Thus, ascarosides suppress type 2 immune response by affecting both innate and adaptive immunity and could define a potent class of small molecule drugs to treat allergic airway diseases.
  • Toshinori Nakayama, Kiyoshi Hirahara, Motoko Y Kimura, Chiaki Iwamura, Masahiro Kiuchi, Kota Kokubo, Atsushi Onodera, Kahoko Hashimoto, Shinichiro Motohashi
    International Immunology 33(12) 699-704 2021年11月25日  査読有り
    <title>Abstract</title> CD4+ T cells not only direct immune responses against infectious micro-organisms but are also involved in the pathogenesis of inflammatory diseases. In the last two to three decades, various researchers have identified and characterized several functional CD4+ T-cell subsets, including T-helper 1 (Th1), Th2, Th9 and Th17 cells and regulatory T (Treg) cells. In this mini-review, we introduce the concept of pathogenic Th cells that induce inflammatory diseases with a model of disease induction by a population of pathogenic Th cells: the ‘pathogenic Th population disease-induction model’. We will focus on Th2 cells that induce allergic airway inflammation—pathogenic Th2 cells (Tpath2 cells)—and discuss the nature of Tpath2 cells that shape the pathology of chronic inflammatory diseases. Various Tpath2-cell subsets have been identified and their unique features are summarized in mouse and human systems. Second, we will discuss how Th cells migrate and are maintained in chronic inflammatory lesions. We propose a model known as the ‘CD69–Myl9 system’. CD69 is a cell surface molecule expressed on activated T cells and interaction with its ligand myosin light chain 9 (Myl9) is required for the induction of inflammatory diseases. Myl9 molecules in the small vessels of inflamed lungs may play a crucial role in the migration of activated T cells into inflammatory lesions. Emerging evidence may provide new insight into the pathogenesis of chronic inflammatory diseases and contribute to the development of new therapeutic strategies for intractable inflammatory disorders.
  • Kiyoshi Hirahara, Ami Aoki, Masahiro Kiuchi, Toshinori Nakayama
    Journal of Allergy and Clinical Immunology 147(6) 2063-2066 2021年6月  査読有り
  • Kiyoshi Hirahara, Kota Kokubo, Ami Aoki, Masahiro Kiuchi, Toshinori Nakayama
    Frontiers in Immunology 12 2021年4月21日  査読有り
    Memory T cells are crucial for both local and systemic protection against pathogens over a long period of time. Three major subsets of memory T cells; effector memory T (TEM) cells, central memory T (TCM) cells, and tissue-resident memory T (TRM) cells have been identified. The most recently identified subset, TRM cells, is characterized by the expression of the C-type lectin CD69 and/or the integrin CD103. TRM cells persist locally at sites of mucosal tissue, such as the lung, where they provide frontline defense against various pathogens. Importantly, however, TRM cells are also involved in shaping the pathology of inflammatory diseases. A number of pioneering studies revealed important roles of CD8+ TRM cells, particularly those in the local control of viral infection. However, the protective function and pathogenic role of CD4+ TRM cells that reside within the mucosal tissue remain largely unknown. In this review, we discuss the ambivalent feature of CD4+ TRM cells in the protective and pathological immune responses. We also review the transcriptional and epigenetic characteristics of CD4+ TRM cells in the lung that have been elucidated by recent technical approaches. A better understanding of the function of CD4+ TRM cells is crucial for the development of both effective vaccination against pathogens and new therapeutic strategies for intractable inflammatory diseases, such as inflammatory bowel diseases and chronic allergic diseases.
  • Masahiro Kiuchi, Atsushi Onodera, Kota Kokubo, Tomomi Ichikawa, Yuki Morimoto, Eiryo Kawakami, Naoya Takayama, Koji Eto, Haruhiko Koseki, Kiyoshi Hirahara, Toshinori Nakayama
    Journal of Experimental Medicine 218(4) 2021年4月5日  査読有り
    Different dynamics of gene expression are observed during cell differentiation. In T cells, genes that are turned on early or turned off and stay off have been thoroughly studied. However, genes that are initially turned off but then turned on again after stimulation has ceased have not been defined; they are obviously important, especially in the context of acute versus chronic inflammation. Using the Th1/Th2 differentiation paradigm, we found that the Cxxc1 subunit of the Trithorax complex directs transcription of genes initially down-regulated by TCR stimulation but up-regulated again in a later phase. The late up-regulation of these genes was impaired either by prolonged TCR stimulation or Cxxc1 deficiency, which led to decreased expression of Trib3 and Klf2 in Th1 and Th2 cells, respectively. Loss of Cxxc1 resulted in enhanced pathogenicity in allergic airway inflammation in vivo. Thus, Cxxc1 plays essential roles in the establishment of a proper CD4+ T cell immune system via epigenetic control of a specific set of genes.
  • Kiyoshi Hirahara, Ami Aoki, Toshinori Nakayama
    Allergology International 70(2) 169-173 2021年4月  査読有り
  • Ami Aoki, Kiyoshi Hirahara, Masahiro Kiuchi, Toshinori Nakayama
    Allergology International 70(1) 3-8 2021年1月  査読有り
    Eosinophils are multifunctional leukocytes, being involved in the host defense against helminth infection, tissue homeostasis and repair of injured tissue. However, eosinophils also play critical roles in shaping the pathogenesis of allergic diseases, including fibrotic responses in allergic diseases. Eosinophils consist of various granules that are a source of cytokines, chemokines, enzymes, extracellular matrix and growth factors. Recent studies have revealed that eosinophil extracellular trap cell death (EETosis) exacerbates eosinophilic inflammation by releasing the products, including Charcot-Leyden crystals (CLCs). In type 2 inflammatory diseases, memory-type pathogenic helper T (Tpath) cells are involved in shaping the pathogenesis of eosinophilic inflammation by recruiting and activating eosinophils in vivo. We herein review the molecular mechanisms underlying the development of eosinophils and the various functions of granules, including CLCs, during eosinophilic inflammation. We also discuss the double-edged roles of eosinophils in tissue repair and type 2 immune inflammation.
  • Yoshihiro Takasato, Yosuke Kurashima, Masahiro Kiuchi, Kiyoshi Hirahara, Sayuri Murasaki, Fujimi Arai, Kumi Izawa, Ayako Kaitani, Kaoru Shimada, Yukari Saito, Shota Toyoshima, Miho Nakamura, Kumiko Fujisawa, Yoshimichi Okayama, Jun Kunisawa, Masato Kubo, Naoki Takemura, Satoshi Uematsu, Shizuo Akira, Jiro Kitaura, Takao Takahashi, Toshinori Nakayama, Hiroshi Kiyono
    Mucosal Immunology 14(3) 640-651 2020年12月10日  査読有り
    <title>Abstract</title>Oral immunotherapy (OIT) is an effective approach to controlling food allergy. Although the detailed molecular and cellular mechanisms of OIT are unknown currently, they must be understood to advance the treatment of allergic diseases in general. To elucidate the mechanisms of OIT, especially during the immunological transition from desensitization to allergy regulation, we generated a clinical OIT murine model and used it to examine immunological events of OIT. We found that in mice that completed OIT successfully, desensitized mast cells (MCs) showed functionally beneficial alterations, such as increased induction of regulatory cytokines and enhanced expansion of regulatory T cells. Importantly, these regulatory-T-cell-mediated inhibitions of allergic responses were dramatically decreased in mice lacking OIT-induced desensitized MC. Collectively, these findings show that the desensitization process modulates the activation of MCs, leading directly to enhanced induction of regulatory-T-cell expansion and promotion of clinical allergic unresponsiveness. Our results suggest that efficiently inducing regulatory MCs is a novel strategy for the treatment of allergic disease.
  • Giuseppe Sciumè, Yohei Mikami, Dragana Jankovic, Hiroyuki Nagashima, Alejandro V. Villarino, Tasha Morrison, Chen Yao, Sadie Signorella, Hong-Wei Sun, Stephen R. Brooks, Difeng Fang, Vittorio Sartorelli, Shingo Nakayamada, Kiyoshi Hirahara, Beatrice Zitti, Fred P. Davis, Yuka Kanno, John J. O’Shea, Han-Yu Shih
    53(4) 745-758.e4 2020年10月  査読有り
  • Akane S. Suzuki, Ryoji Yagi, Motoko Y. Kimura, Chiaki Iwamura, Kenta Shinoda, Atsushi Onodera, Kiyoshi Hirahara, Damon J. Tumes, Ryo Koyama-Nasu, Siiri E. Iismaa, Robert M. Graham, Shinichiro Motohashi, Toshinori Nakayama
    Frontiers in Immunology 11 1536-1536 2020年7月21日  査読有り
  • Takahiro Aoki, Mariko Takami, Tomozumi Takatani, Kiwamu Motoyoshi, Ayana Ishii, Ayaka Hara, Takahide Toyoda, Reona Okada, Moeko Hino, Ryo Koyama‐Nasu, Masahiro Kiuchi, Kiyoshi Hirahara, Motoko Y. Kimura, Toshinori Nakayama, Naoki Shimojo, Shinichiro Motohashi
    Cancer Science 111(7) 2223-2233 2020年7月  査読有り
    Invariant natural killer T (iNKT) cells are innate-like CD1d-restricted T cells that express the invariant T cell receptor (TCR) composed of Vα24 and Vβ11 in humans. iNKT cells specifically recognize glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d. iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens. However, iNKT cell recognition of CD1d-negative tumor cells is unknown, and direct cytotoxicity of iNKT cells toward CD1d-negative tumor cells remains controversial. Here, we demonstrate that activated iNKT cells recognize leukemia cells in a CD1d-independent manner, however still in a TCR-mediated way. iNKT cells degranulated and released Th1 cytokines toward CD1d-negative leukemia cells (K562, HL-60, REH) as well as αGalCer-loaded CD1d-positive Jurkat cells. The CD1d-independent cytotoxicity was enhanced by natural killer cell-activating receptors such as NKG2D, 2B4, DNAM-1, LFA-1 and CD2, but iNKT cells did not depend on these receptors for the recognition of CD1d-negative leukemia cells. In contrast, TCR was essential for CD1d-independent recognition and cytotoxicity. iNKT cells degranulated toward patient-derived leukemia cells independently of CD1d expression. iNKT cells targeted myeloid malignancies more than acute lymphoblastic leukemia. These findings reveal a novel anti-tumor mechanism of iNKT cells in targeting CD1d-negative tumor cells and indicate the potential of iNKT cells for clinical application to treat leukemia independently of CD1d.
  • Göschl, L, Preglej, T, Boucheron, N, Saferding, V, Müller, L, Platzer, A, Hirahara, K, Han-Yu, S, Backlund, J, Matthias, P, Niederreiter, B, Hladik, A, Kugler, M, Gualdoni, G, Scheinecker, C, Knapp, S, Seiser, C, Holmdahl, R, Tillmann, K, Plasenzotti, R, Podesser, B, Aletaha, D, Smolen, Karonitsch, TJ, Steiner, G, Ellmeier, W, Bonelli, M
    J. Autoimmun. MAR(108) 102379-102379 2020年3月  査読有り
  • Kiyoshi Hirahara, Toshinori Nakayama
    Mucosal Vaccines 133-142 2020年  査読有り
  • Tomomi Ichikawa, Kiyoshi Hirahara, Kota Kokubo, Masahiro Kiuchi, Ami Aoki, Yuki Morimoto, Jin Kumagai, Atsushi Onodera, Naoko Mato, Damon J Tumes, Yoshiyuki Goto, Koichi Hagiwara, Yutaka Inagaki, Tim Sparwasser, Kazuyuki Tobe, Toshinori Nakayama
    20(11) 1469-1480 2019年11月  査読有り
  • Damon Tumes, Kiyoshi Hirahara, Magdalene Papadopoulos, Kenta Shinoda, Atsushi Onodera, Jin Kumagai, Kwok Ho Yi, Harshita Pant, Kota Kokubo, Masahiro Kiuchi, Ami Aoki, Kazushige Obata-Ninomiya, Koji Tokoyoda, Yusuke Endo, Motoko Y Kimura, Toshinori Nakayama
    144(2) 549-560 2019年8月  査読有り
  • Hirahara, K
    Semin. Immunopathol. 41(3) 279-281 2019年5月  査読有り
  • Hirahara, K, Aoki, A, Morimoto, Y, Kiuchi, M, Okano, M, Nakayama, T
    Semin. Immunopathol. 4(3) 339-348 2019年5月  査読有り
  • Hirahara, K, Shinoda, K, Morimoto, Y, Kiuchi, M, Aoki, A, Kumagai, J, Kokubo, K, Nakayama, T
    Front. Immunol. 26(10) 570-570 2019年3月  査読有り
  • Wada T, Hirahara K, Aoki A, Morimoto Y, Kiuchi M, Kumagai J, Okano M, Kokubo K, Kato M, Fukano C, Ohashi-Doi K, Nakayama T
    Journal of immunological methods 465 53-60 2019年2月  査読有り
  • Ito Toshihiro, Hirahara Kiyoshi, Nasu Ryo, Yano Ikuya, Motohashi Shinichiro, Nakayama Toshinori
    CANCER SCIENCE 109(9) 1269-421 2018年12月  査読有り
  • Hirahara Kiyoshi, Mato Naoko, Hagiwara Koichi, Nakayama Toshinori
    JOURNAL OF LEUKOCYTE BIOLOGY 104(5) 895-901 2018年11月  査読有り
  • Obata-Ninomiya K, Ishiwata K, Nakano H, Endo Y, Ichikawa T, Onodera A, Hirahara K, Okamoto Y, Kanuka H, Nakayama T
    Proceedings of the National Academy of Sciences of the United States of America 115(42) E9849-E9858 2018年10月16日  査読有り
  • Yamamoto T, Endo Y, Onodera A, Hirahara K, Asou HK, Nakajima T, Kanno T, Ouchi Y, Uematsu S, Nishimasu H, Nureki O, Tumes DJ, Shimojo N, Nakayama T
    Nature communications 9(1) 4231 2018年10月12日  査読有り
  • Hirahara Kiyoshi, Shinoda Kenta, Endo Yusuke, Ichikawa Tomomi, Nakayama Toshinori
    INFLAMMATION AND REGENERATION 38(10) 2018年6月  査読有り
  • T. Iinuma, Y. Okamoto, Y. Morimoto, T. Arai, T. Sakurai, S. Yonekura, D. Sakurai, K. Hirahara, T. Nakayama
    Allergy: European Journal of Allergy and Clinical Immunology 73(2) 479-489 2018年2月1日  査読有り
    Background: Allergic rhinitis (AR) consists of three developmental stages that are based on the presence/absence of antigen-specific IgE and symptoms. The pathogenic Th2 (Tpath2) cells constitute a population of Th2 cells with additional potentially pathogenic characteristics. We examined the relationship between Tpath2 cells and the stages of allergic rhinitis by focusing on ST2, which is an IL-33 receptor. Methods: Patients with Japanese cedar pollen-induced AR (JCP-AR) and healthy volunteers were divided into “nonsensitized,” “asymptomatic sensitized (AS),” and “JCP-AR” groups. We analyzed the ST2 expression and the Th2 function of cultured CD4+ T cells. Next, we observed the progress of patients in the AS stage around the time of seasonal pollen dispersal, with the characteristics of Th2 cells. Results: The ST2 expression of T cells was only upregulated in the AR group. The production of IL-4 and IL-13 was found in CD4+ T cells obtained from AS by stimulation with JCP, but reactivity to IL-33 was not observed. Although IL-33 did not induce the elevation of IL-4 production in the JCP-AR group, IL-33 substantially increased the production of IL-5 and IL-13 in comparison with antigen stimulation alone. In newly afflicted patients, the increased expression of ST2 and elevated reactivity to IL-33 was observed, even before the pollen dispersal season. Conclusions: Our study demonstrated that the pathogenicity of memory Th2 cells is linked to sensitization and the stage of allergic rhinitis. Therefore, Tpath2 cells may provide useful insights into the mechanism of the onset and progression of allergic rhinitis.
  • Lisa Göschl, Teresa Preglej, Patricia Hamminger, Michael Bonelli, Liisa Andersen, Nicole Boucheron, Alexandra F. Gülich, Lena Müller, Victoria Saferding, Ilgiz A. Mufazalov, Kiyoshi Hirahara, Christian Seiser, Patrick Matthias, Thomas Penz, Michael Schuster, Christoph Bock, Ari Waisman, Günter Steiner, Wilfried Ellmeier
    86 51-61 2018年1月1日  査読有り
  • Yuki Morimoto, Kiyoshi Hirahara, Masahiro Kiuchi, Tomoko Wada, Tomomi Ichikawa, Toshio Kanno, Mikiko Okano, Kota Kokubo, Atsushi Onodera, Daiju Sakurai, Yoshitaka Okamoto, Toshinori Nakayama
    Immunity 49(1) 134-+ 2018年  査読有り
    Memory T cells provide long-lasting protective immunity, and distinct subpopulations of memory T cells drive chronic inflammatory diseases such as asthma. Asthma is a chronic allergic inflammatory disease with airway remodeling including fibrotic changes. The immunological mechanisms that induce airway fibrotic changes remain unknown. We found that interleukin-33 (IL-33) enhanced amphiregulin production by the IL-33 receptor, ST2hi memory T helper 2 (Th2) cells. Amphiregulin-epidermal growth factor receptor (EGFR)-mediated signaling directly reprogramed eosinophils to an inflammatory state with enhanced production of osteopontin, a key profibrotic immunomodulatory protein. IL-5-producing memory Th2 cells and amphiregulin-producing memory Th2 cells appeared to cooperate to establish lung fibrosis. The analysis of polyps from patients with eosinophilic chronic rhinosinusitis revealed fibrosis with accumulation of amphiregulin-producing CRTH2hiCD161hiCD45RO+CD4+ Th2 cells and osteopontin-producing eosinophils. Thus, the IL-33-amphiregulin-osteopontin axis directs fibrotic responses in eosinophilic airway inflammation and is a potential target for the treatment of fibrosis induced by chronic allergic disorders. Asthma is a chronic allergic inflammatory disease with airway remodeling including fibrotic changes. Morimoto and colleagues find that the IL-33-ST2-amphiregulin-EGRF-osteopontin axis directs fibrotic responses in chronic allergic inflammation with the involvement of airway epithelial cells, pathogenic memory Th2 cells, and inflammatory eosinophils in both mouse and human.
  • Toshihiro Ito, Kiyoshi Hirahara, Atsushi Onodera, Ryo Koyama-Nasu, Ikuya Yano, Toshinori Nakayama
    International Immunology 29(9) 411-421 2017年9月  査読有り
  • Atsushi Onodera, Masahiro Kiuchi, Kota Kokubo, Miki Kato, Tomohiro Ogino, Shu Horiuchi, Urara Kanai, Kiyoshi Hirahara, Toshinori Nakayama
    JOURNAL OF IMMUNOLOGY 199(3) 1153-1162 2017年8月  査読有り
    Posttranslational modifications of histones are well-established epigenetic modifications that play an important role in gene expression and regulation. These modifications are partly mediated by the Trithorax group (TrxG) complex, which regulates the induction or maintenance of gene transcription. We investigated the role of Menin, a component of the TrxG complex, in the acquisition and maintenance of Th2 cell identity using T cell-specific Menin-deficient mice. Our gene expression analysis revealed that Menin was involved in the maintenance of the high expression of the previously identified Th2-specific genes rather than the induction of these genes. This result suggests that Menin plays a role in the maintenance of Th2 cell identity. Menin directly bound to the Gata3 gene locus, and this Menin-Gata3 axis appeared to form a core unit of the Th2-specific gene regulatory network. Consistent with the phenotype of Menin-deficient Th2 cells observed in vitro, Menin deficiency resulted in the attenuation of effector Th2 cell-induced airway inflammation. In addition, in memory Th2 (mTh2) cells, Menin was found to play an important role in the maintenance of the expression of Th2-specific genes, including Gata3, Il4, and Il13. Consequently, Menin-deficient mTh2 cells showed an impaired ability to recruit eosinophils to the lung, resulting in the attenuation of mTh2 cell-induced airway inflammation. This study confirmed the critical role of Menin in Th2 cell-mediated immune responses.
  • Damon J. Tumes, Magdalene Papadopoulos, Yusuke Endo, Atsushi Onodera, Kiyoshi Hirahara, Toshinori Nakayama
    IMMUNOLOGICAL REVIEWS 278(1) 8-19 2017年7月  査読有り
    An estimated 300 million people currently suffer from asthma, which causes approximately 250 000 deaths a year. Allergen-specific T-helper (Th) cells produce cytokines that induce many of the hallmark features of asthma including airways hyperreactivity, eosinophilic and neutrophilic inflammation, mucus hypersecretion, and airway remodeling. Cytokine-producing Th subsets including Th1 (IFN-gamma), Th2 (IL-4, IL-5, IL-13), Th9 (IL-9), Th17 (IL-17), Th22 (IL-22), and T regulatory (IL-10) cells have all been suggested to play a role in the development of asthma. Th differentiation involves genetic regulation of gene expression through the concerted action of cytokines, transcription factors, and epigenetic regulators. We describe how Th differentiation and plasticity is regulated by epigenetic histone and DNA modifications, with a focus on the regulation of histone methylation by members of the polycomb and trithorax complexes. In addition, we outline environmental influences that could influence epigenetic regulation of Th cells and discuss the potential to regulate Th plasticity and function through drugs targeting the epigenetic machinery. It is also becoming apparent that epigenetic regulation of allergen-specific memory Th cells may be important in the development and persistence of chronic allergies. Finally, we describe how epigenetic modifiers regulate cytokine memory in Th cells and describe recently identified hybrid, plastic, and pathogenic memory Th subsets the context of allergic asthma.
  • Naoko Mato, Kiyoshi Hirahara, Tomomi Ichikawa, Jin Kumagai, Masayuki Nakayama, Hideaki Yamasawa, Masashi Bando, Koichi Hagiwara, Yukihiko Sugiyama, Toshinori Nakayama
    SCIENTIFIC REPORTS 7(1) 6805 2017年7月  査読有り
    The lung develops an unique epithelial barrier system to protect host from continuous invasion of various harmful particles. Interleukin (IL-)33 released from epithelial cells in the lung drives the type 2 immune response by activating ST2-expressed immune cells in various allergic diseases. However, the involvement of memory-type ST2(+)CD4(+)T cells in such lung inflammation remains unclear. Here we demonstrated that intratracheal administration of IL-33 resulted in the substantial increase of numbers of tissue-resident memory-type ST2(+)CD4(+)T cells in the lung. Following enhanced production of IL-5 and IL-13, eosinophilic lung inflammation sequentially developed. IL-33-mediated eosinophilic lung inflammation was not fully developed in T cell-deficient Foxn1(nu) mice and NSG mice. Dexamethasone treatment showed limited effects on both the cell number and function of memory-type ST2(+)CD4(+)T cells. Thus our study provides novel insight into the pathogenesis of eosinophilic lung disease, showing that memory-type ST2(+)CD4(+)T cells are involved in IL-33-induced eosinophilic inflammation and elicited steroid-resistance.
  • Kenta Shinoda, Kiyoshi Hirahara, Toshinori Nakayama
    ALLERGOLOGY INTERNATIONAL 66(3) 369-376 2017年7月  査読有り
    Immunological memory is an important protective mechanism that enables host organisms to respond rapidly and vigorously to pathogens that have been previously encountered. In addition to the protective function, memory CD4(+) T helper (Th) cells play a central role in the pathogenesis of chronic inflammatory disorders, including asthma. Recently, several investigators have identified phenotypically and functionally distinct memory Th2 cell subsets that produce IL-5. These memory Th2 cell subsets play an important role in the pathology of allergic inflammation and function as memory-type "pathogenic Th2 (Tpath2) cells" both in mice and humans. We review the role of lung Tpath2 cells in the development of allergic inflammation and, in the context of recent findings, propose a mechanism by which Tpath2 cells not only survive but also continue to function at the sites where antigens were encountered. A greater understanding of the functional molecules or signaling pathways that regulate the inflammatory niche for Tpath2 cells may aid in the design of more effective treatments for chronic inflammatory disorders. Copyright (C) 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V.

MISC

 63

書籍等出版物

 5

講演・口頭発表等

 147

共同研究・競争的資金等の研究課題

 15

産業財産権

 1